PTO/SB/08x (08-03.)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

Under the Pipermosis Reduction Act of 1995, no persons are required to equilection of inflamentation science a valid CMB centre in Application Number 10559262.

Application Number 1055926.

		Filing Date	2006-04-03	
	First Named Inventor Yası		hiro HORIIKE	
	STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		
	(Hot of Submission ander or of it ison	Examiner Name		
		Attorney Docket Numb	er	RHM-US030695

					U.S.I	PATENTS			Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Date	Name of Pate of cited Docu	entee or Applicant ment	Releva	Columns,Lines where ant Passages or Relevant s Appear
	1	4883763		1989-1	1-28	Holen et al.			
	2	6399361		2002-0	6-04	Brotherston e	tal.		
	3	4788154		1988-1	1-29	Guigan			
	4	4892708		1990-0	1-09	Wogoman			
If you wish	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add
			U.S.P	ATENT	APPLIC	CATION PUB	LICATIONS		Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ation	Name of Pate of cited Docu	entee or Applicant iment	Releva	Columns,Lines where ant Passages or Relevant s Appear
	1								
If you wisi	h to a	dd additional U.S. Publi	shed Ap					d button	
				FOREIG	GN PAT	TENT DOCUM	ENTS		Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country	y Code ²	Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear

INFORMATION DISCLOSURE			Date			2006-04-03			
			First Named Inventor Yasuf			thiro HORIIKE			
			Art Unit						
(Not let submission dider of or it issay		Exami	Examiner Name						
		Attorne	Attorney Docket Number			RHM-US030695			
					\neg			Т	
			١. ا		ι I.			L	

Application Number

10595262

1	2003/83958	JP	A	2003-03-19	KIKUCHI et al.	V
2	2004/109082	JP	A	2004-04-08	Japan Science & Technology Corp.	Z
3	2004/109099	JP	A	2004-04-08	KIKUCHI et al.	V

	3	2004/109099	JP	A	2004-04-08	KIKUCHI et al.		V	
If you wish to add additional Foreign Patent Document citation information please click the Add button Add									

	3	2004/109099	JP	A	2004-04-08	KIKUCHI et al.		Z
If you wish to add additional Foreign Patent Document citation information please click the Add button Add								
NON-PATENT LITERATURE DOCUMENTS Remove								
leading name of the outbox (in CADITAL LETTERS) title of the ordists (when appropriate) title of the item								

If you wish to add additional Foreign Patent Document citation information please click the Add button Add								
NON-PATENT LITERATURE DOCUMENTS Remove								
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher							T5	

If you wish to add additional non-patent literature document citation information please click the Add button Add FYAMINER SIGNATURE Examiner Signature Date Considered *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3), 3 For Japanese patent documents, the indication of the year of the reion of the Emperor must precede the senal number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

		. ++			
		Filing Date		2006-04-03	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Yasu		ihiro HORIIKE	
	(Not for submission under 37 CFR 1.99)	Art Unit			
ľ	······································	Examiner Name			
		Attorney Docket Numb	er	RHM-US030695	

10505363

Application Number

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

√ None

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to tife (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to stee! In our to complete, including galatining, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggesterior for reducing this burder, should be sent the fold-left information Officer U.S. Pattert and Trademark Office. U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 2213-1450, DO NOT SEND TESTED AND ADDRESS. SEND TO: Commissioner for Paterias, P.O. Box 1450, Alexandria,

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is SU U.S. C. (2)(2)(2) (2) famishing of the information solicide is voluntary, and (3) the principal purpuses for which the information is used by the U.S. Patient and Trademan Kolline is to process another examines your submission related to a patient application or patient. If you do not furnish the requested process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission, which may related the process and/or examines your submission, which may related the process and/or examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disease records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S. C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, cuting an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make indemninations a partial individuals.
 - 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1-14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.